BICYCLE THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.41 USD | +2.99% |
|
+3.72% | +29.48% |
Chart calendar Bicycle Therapeutics plc
ac.4V2HlTTWhYI7bXdW9_gd1wNIwEqv_QtOXDZknaRbqfc.rDzBw36Otc0JFw8uv7t77mA9qC7atUQ5MEIU85Aq2a-MBOjvAY70xmQyTw~48085472261559fadae1652572f3f20d
Upcoming events on Bicycle Therapeutics plc
Past events on Bicycle Therapeutics plc
| 10/04/2024 02:00 am | American Association for Cancer Research Meeting - Abstract Number: 5807 |
| 10/04/2024 02:00 am | American Association for Cancer Research Meeting - Abstract Number: 5301 |
| 09/04/2024 08:30 pm | Needham Healthcare Conference |
| 08/04/2024 09:30 pm | American Association for Cancer Research Meeting - Abstract Number: 1340 |
| 14/03/2024 06:00 pm | Barclays Global Healthcare Conference - Fireside Chat |
| 11/03/2024 09:30 pm | Leerink Partners Global Biopharma Conference |
| 06/03/2024 09:40 pm | TD Cowen Health Care Conference - Fireside Chat |
| 20/02/2024 05:35 pm | Q4 2023 Earnings Release |
| 14/02/2024 08:30 pm | Oppenheimer Healthcare Life Sciences Conference |
| 18/01/2024 09:30 pm | B. Riley Securities Oncology Conference - Track 1 |
| 14/12/2023 06:30 pm | R&D Day |
| 15/11/2023 03:30 pm | Jefferies London Healthcare Conference - Fireside Chat |
| 03/11/2023 07:30 pm | TD Cowen Fall Oncology Innovation Summit - Fireside Chat |
| 02/11/2023 04:30 pm | Q3 2023 Earnings Release |
| 12/09/2023 07:40 pm | Morgan Stanley Global Healthcare Conference - Fireside Chat |
| 11/09/2023 05:30 pm | BT8009 Phase 2/3 Study Results Call |
| 03/08/2023 04:29 pm | Q2 2023 Earnings Release |
| 20/06/2023 10:00 pm | TD Cowen Radiopharmaceutical Innovation Summit |
| 13/06/2023 04:30 pm | Annual General Meeting |
| 07/06/2023 08:00 pm | Jefferies Global Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 13,8 9,99 38.18% | 10,4 9,30 11.76% | 11,7 13,3 -12.02% | 14,5 14,9 -2.74% | 27,0 29,9 -9.73% | 28,0 |
|
EBITDA Million USD | Released Forecast Spread | -25,3 -27,3 7.21% | -50,7 -36,3 -39.65% | -64,2 -62,3 -3.14% | -113 -112 -0.47% | -183 -167 -9.85% | -207 |
|
EBIT Million USD | Released Forecast Spread | -26,3 -30,6 14.04% | -52,0 -44,9 -15.6% | -65,6 -64,4 -1.96% | -117 -116 -0.62% | -190 -187 -1.43% | -235 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -30,9 -34,1 9.41% | -51,7 -45,4 -13.83% | -68,5 -66,9 -2.38% | -114 -116 1.5% | -179 -185 3.2% | -233 |
|
Net income Million USD | Released Forecast Spread | -30,6 -34,0 9.98% | -51,0 -44,9 -13.62% | -66,8 -65,6 -1.82% | -113 -115 1.96% | -181 -185 2.56% | -228 |
|
EPS USD | Released Forecast Spread | -2,77 -2,31 -19.74% | -2,66 -2,31 -14.94% | -2,67 -2,69 0.71% | -3,80 -3,85 1.38% | -5,08 -5,32 4.56% | -5,30 |
| Announcement Date | 10/03/20 | 11/03/21 | 01/03/22 | 28/02/23 | 20/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 3,77 5,31 -28.99% | 3,86 4,41 -12.49% | 4,38 3,69 18.7% | 3,04 5,58 -45.51% | 3,19 3,55 -10.37% | 4,90 7,72 -36.59% | 11,4 12,9 -11.79% | 5,35 13,8 -61.12% | 5,33 6,88 -22.48% | 6,03 | 6,29 | 6,34 | 7,44 | 5,00 |
|
EBIT Million USD | Released Forecast Spread | -18,0 -16,8 -7.04% | -27,4 -19,1 -43.25% | -27,3 -24,8 -9.89% | -29,8 -27,0 -10.29% | -32,2 -31,5 -2.25% | -41,8 -26,2 -59.63% | -43,1 -31,3 -37.82% | -50,8 -42,4 -19.78% | -54,2 -53,4 -1.48% | -55,0 | -58,1 | -60,5 | -60,8 | -75,5 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -18,8 -17,2 -9.09% | -28,0 -19,4 -43.91% | -27,3 -25,5 -6.87% | -28,6 -27,5 -3.93% | -30,4 -32,1 5.38% | -39,7 -32,4 -22.39% | -43,1 -29,6 -45.66% | -47,6 -41,6 -14.43% | -48,8 -54,5 10.56% | -55,1 | -58,5 | -60,4 | -61,4 | -71,3 |
|
Net income Million USD | Released Forecast Spread | -18,0 -16,7 -8.12% | -27,6 -19,7 -40.1% | -26,8 -25,2 -6.48% | -28,3 -28,1 -0.79% | -30,0 -32,1 6.54% | -39,1 -32,3 -20.9% | -42,6 -30,8 -38.3% | -49,9 -42,1 -18.48% | -49,1 -53,5 8.21% | -54,0 | -57,4 | -60,1 | -60,5 | -71,3 |
|
EPS USD | Released Forecast Spread | -0,63 -0,61 -2.97% | -0,93 -0,67 -39.01% | -0,90 -0,86 -4.43% | -0,96 -0,91 -6.08% | -1,01 -1,07 5.83% | -1,30 -1,08 -20.18% | -1,41 -1,02 -37.67% | -1,26 -1,13 -11.15% | -1,16 -1,31 11.27% | -1,28 | -1,35 | -1,39 | -1,37 | -1,44 |
| Announcement Date | 01/03/22 | 05/05/22 | 04/08/22 | 03/11/22 | 28/02/23 | 04/05/23 | 03/08/23 | 02/11/23 | 20/02/24 | - | - | - | - | - |
| Today 01:35 am | EXELIXIS, INC.: Q1 2024 Earnings Release |
| 01/05/2024 | SUMMIT THERAPEUTICS INC.: Q1 2024 Earnings Release |
| 01/05/2024 | MACROGENICS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | REGENXBIO INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 | DECIPHERA PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
| 01/05/2024 04:30 pm | NEUROCRINE BIOSCIENCES, INC.: Q1 2024 Earnings Release |
| 02/05/2024 01:35 am | SAREPTA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 | ZENTALIS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 | DENALI THERAPEUTICS INC.: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 | GERON CORPORATION: Q1 2024 Earnings Release |
Past sector events for Bicycle Therapeutics plc
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- BCYC Stock
- Calendar Bicycle Therapeutics plc
